All:
As previously documented to death, alternate day fasting (ADF -- AKA EOD, Intermittent Fasting (IF)), etc provides no lifespan benefit to normal, healthy, well-fed, non-toxin-megadosed, non-genetically-fucked-up rodents, except to the degree there is a concomitant reduction in Calorie intake; and, even the favorable-looking short-term health risk factor shifts observed in EOD in rodents are mostly not observed in humans. Two recent studies, found by Al Pater on the CR Society list, find that EOD is also not protective against model prostate cancer in mice.
Caloric restriction (CR) delays cancer growth in animals, though translation to humans is difficult. We hypothesized intermittent fasting (i.e., intermittent extreme CR), may be better tolerated and prolong survival of prostate cancer (CaP) bearing mice.
METHODS: We conducted a pilot study by injecting 105 male individually-housed SCID [immunodeficient] mice with LAPC-4 cells. When tumors reached 200 mm(3), 15 mice/group were randomized to one of seven diets and sacrificed when tumors reached 1,500 mm(3): Group 1: ad libitum 7 days/week; Group 2: fasted 1 day/week and ad libitum 6 days/week; Group 3: fasted 1 day/week and fed 6 days/week via paired feeding to maintain isocaloric conditions to Group 1; Group 4: 14% CR 7 days/week; Group 5: fasted 2 days/week and ad libitum 5 days/week; Group 6: fasted 2 day/week and fed 5 days/week via paired feeding to maintain isocaloric conditions to Group 1; Group 7: 28% CR 7 days/week. Sera from mice at sacrifice were analyzed for IGF-axis hormones.
RESULTS: There were no significant differences in survival among any groups. However, relative to [AL], there were non-significant trends for for improved survival for Groups 3 (HR 0.65, P = 0.26), 5 (0.60, P = 0.18), 6 (HR 0.59, P = 0.16), and 7 (HR = 0.59, P = 0.17). Relative to Group 1, body weights and IGF-1 levels were significantly lower in Groups 6 and 7.
CONCLUSIONS: This exploratory study found non-significant trends toward improved survival with some intermittent fasting regimens, in the absence of weight loss. Larger appropriately powered studies to detect modest, but clinically important differences are necessary to confirm these findings.(1)
Ie, despite the lack of a significant effect, with only 15 animals per group, it's reasonable to suspect that this was just an artifact of the study being underpowered, and that there might be some there there. This is especially so since "mild" CR has been shown in several previous studies to be protective in a range of prostate cancer models, and yet in this study its nominal "benefit" did not reach statistical significance, despite being tied for the largest numerical hazard ratio reduction and p-value.
So, they did another study, using only the promising-looking twice-weekly fasting group, and including more animals in each arm:
We sought to confirm these findings in a larger study. A total of 100 (7- to 8-week-old) male severe combined immunodeficiency mice were injected subcutaneously with 1 x 10(5) LAPC-4 prostate cancer cells. Mice were randomized to either ad libitum Western Diet (44% carbohydrates, 40% fat and 16% protein) or ad libitum Western Diet with twice-weekly 24 h fasts (IF). ... Overall, there was no difference in mouse survival (P=0.37) or tumor volumes (P>/=0.10) between groups. Mouse body weights were similar between arms (P=0.84). IF mice had significantly higher serum IGF-1 levels and IGF-1/IGFBP-3 ratios at killing (P<0.001). [Mattson has reported this same finding, exactly the opposite of CR proper -MR] However, no difference was observed in serum insulin, IGFBP-3 or tumor phospho-Akt levels (P>/=0.39). IF did not improve mouse survival nor did it delay prostate tumor growth.
This may be secondary to metabolic adaptations to the 24 h fasting periods. Future studies are required to optimize CR for application in humans.
Full texts are linked by PMID below.
References
1. Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. Buschemeyer WC 3rd, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, Cohen P, Hwang D, Johnson TL, Freedland SJ. Prostate. 2010 Feb 17. [Epub ahead of print] PMID: 20166128
2. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Prostate Cancer Prostatic Dis. 2010 Aug 24. [Epub ahead of print] PMID: 20733612